PhaseRx (PZRX) Stock Price, News & Analysis

Company Overview

PhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.

Key Stats

• Today's Range: $0.28 to $0.34
• 50-Day Range: $0.28 to $0.28
• 52-Week Range: $0.22 to $1.95
• Volume: 1.05 million shs
• Average Volume: 1.24 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PZRX Stock Analysis - Frequently Asked Questions

How were PhaseRx's earnings last quarter?

PhaseRx, Inc. (NASDAQ:PZRX) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.14.

When did PhaseRx IPO?

PhaseRx (PZRX) raised $18 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 3,700,000 shares at $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners acted as the underwriters for the IPO.

What other stocks do shareholders of PhaseRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO) and Net Element (NETE).

Company Calendar

• Last Earnings: 11/09/2017
• Today: 5/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:PZRX
• CIK: 1429386
• Web: phaserx.com
• Phone: (206) 805-6300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A